Epithelial ovarian cancer cell lines spontaneously derived from solid tumor pre-treatment
| Inventor | Institute |
|---|---|
| Anne-Marie Mes-Masson and Diane Provencher | Centre Hospitalier de Luniversité de Montréal |
| SKU: | 161773 |
|---|---|
| Product description: | Epithelial ovarian cancer cell lines spontaneously derived from solid tumor pre-treatment. Cell line aquired resistance to carboplatin |
| Alternate name: | OV-2295 |
| Gender: | Female |
| CRISPR: | No |
| Production details: | Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement. |
| Additional notes: | Patient 2295 was diagnosed with ovarian cancer following imaging, ascites puncture, and partial ommentectomy. Patient was included in a clinical trial and treated with cisplatin/topotecan for the first four months following diagnosis. From months 4-7, patient received carboplatin and paclitaxel and responded well to chemotherapy initially. Three months after the end of chemotherapy however, ascites volume increased and later underwent ovarian cytoreduction. Eleven months after diagnosis, she … |
| Cellosaurus ID: | CVCL_9T13 |
| Receptors of note: | No |
| Cat. #: | 161773 |
|---|---|
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Derived from ascites of patient diagnosed with high-grade serous ovarian cancer |
| Gender: | Female |
| Morphology: | Expresssion of tumor suppressor p53 present. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: semi-compact |
| Growth properties: | Adherent |
| Primary citation: | Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248 |
| Shipping conditions: | Dry Ice |
|---|---|
| Growth medium: | OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin |
| Atmosphere: | Hypoxic condition of 5%O2 and 5%CO2 |
| References: |
Tomas et al. 2023. J Ovarian Res. 11 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4 12:856424. PMID: 35600398 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.